EPAS1 and prostate neoplasm: Next, we characterize at the molecular level prostate tumors at the time of biopsies evaluating, as novel prognostic biomarkers, eNOS, HIF-2α, and β4 integrin by immunohistochemistry (IHC) and, in parallel, H19 and CDH1 RNA levels by ddPCR.